uniQure (NASDAQ:QURE) CEO Matthew C. Kapusta Sells 6,717 Shares

uniQure (NASDAQ:QURE) CEO Matthew C. Kapusta sold 6,717 shares of the company’s stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $11.32, for a total value of $76,036.44. Following the completion of the sale, the chief executive officer now directly owns 580,795 shares in the company, valued at approximately $6,574,599.40. The trade was a 1.14 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

uniQure Stock Up 3.4 %

Shares of NASDAQ QURE opened at $12.07 on Friday. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. The stock has a market capitalization of $588.33 million, a PE ratio of -2.43 and a beta of 0.38. The firm has a fifty day moving average of $15.12 and a 200-day moving average of $9.75. uniQure has a 52-week low of $3.73 and a 52-week high of $19.18.

Analysts Set New Price Targets

Several analysts have recently issued reports on the company. The Goldman Sachs Group upped their price objective on uniQure from $9.00 to $20.00 and gave the company a “neutral” rating in a research report on Thursday, December 12th. HC Wainwright raised their price target on shares of uniQure from $25.00 to $70.00 and gave the stock a “buy” rating in a research note on Monday, January 27th. StockNews.com upgraded shares of uniQure to a “sell” rating in a report on Wednesday, February 5th. Cantor Fitzgerald upped their price objective on shares of uniQure from $28.00 to $58.00 and gave the company an “overweight” rating in a research note on Tuesday, December 10th. Finally, Leerink Partners lifted their target price on shares of uniQure from $26.00 to $44.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 11th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, six have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, uniQure presently has a consensus rating of “Moderate Buy” and an average price target of $40.00.

Institutional Investors Weigh In On uniQure

Several institutional investors and hedge funds have recently added to or reduced their stakes in QURE. RTW Investments LP acquired a new position in shares of uniQure in the 3rd quarter valued at about $49,000. China Universal Asset Management Co. Ltd. lifted its position in uniQure by 57.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock valued at $50,000 after buying an additional 3,663 shares in the last quarter. Atria Investments Inc purchased a new stake in uniQure during the third quarter worth approximately $53,000. Quarry LP purchased a new stake in uniQure during the third quarter worth approximately $58,000. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of uniQure in the 3rd quarter valued at $69,000. 78.83% of the stock is currently owned by institutional investors and hedge funds.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.